{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 103 of 169', '2. For each of the 100 copies of the dataset, an ANCOVA model will be fitted to the', 'SCORAD value at Week 2 in the placebo group. The model will include effects of', 'baseline SCORAD as a covariate, and region and baseline disease severity (IGA 3 or', '4) as factors. The estimated parameters, and their variances, will be used to impute', 'missing values at Week 2 for the placebo group as well as the tralokinumab group', '(seed=11109925).', '3. For each of the 100 copies of the dataset, missing values at Week 4 will be imputed in', 'the same way as for Week 2. The imputations will be based on a similar ANCOVA', 'model, but with SCORAD value at Week 2 included as an additional covariate. The', 'parameters from the model will be estimated based on data from the placebo group.', 'The estimated parameters, and their variances, will be used to impute missing values', 'at Week 4 for both treatment groups.', '4. This stepwise procedure will then be repeated sequentially for Week 6, 8, 10, 12, 14,', 'and 16 with the SCORAD values from the preceding two visits included as covariates', 'in addition to baseline SCORAD as a covariate, and region and baseline disease', 'severity as factors.', 'For each of the 100 imputed dataset, the change from baseline in SCORAD at Week 16 will', 'be analysed using an ANCOVA model with effects of treatment, region, baseline disease', 'severity (IGA 3 or 4), and baseline SCORAD value. The estimated difference at Week 16 will', 'be derived together with the associated standard error. The estimates and standard errors from', \"the 100 analyses are pooled to one estimate and associated standard error using Rubin's rule\", 'to draw inference. From these pooled estimates, the 95% CI for the treatment difference will', 'be calculated.', '12.3.5.2.2 Secondary estimand for the continuous secondary endpoints:', '\"treatment policy\\'', 'The secondary estimand for the continuous secondary endpoints will be:', 'Treatment difference in change from baseline to Week 16 in SCORAD and', 'DLQI, respectively, between tralokinumab and placebo regardless of rescue', 'medication use and treatment discontinuation.', 'The secondary estimand assesses the average difference in change from baseline in SCORAD', 'and DLQI after 16 weeks, resulting from initiation of a treatment regimen with tralokinumab', 'and additional rescue medication as compared to a treatment regimen with placebo and', 'additional rescue medication.', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 104 of 169', 'Primary analyses for the secondary estimand (continuous secondary endpoints)', 'Data retrieved at Week 16 for subjects who have permanently discontinued IMP prior to', 'Week 16 will be included in the analysis. Missing Week 16 data will be imputed using', 'multiple imputations assuming that data is missing at random within the groups used for', 'imputation.', 'Imputation of missing data at Week 16 will be done using multiple imputations within', '4 groups defined according to randomised treatment arm and whether or not subjects have', 'discontinued treatment prior to Week 16. Within a given treatment arm, retrieved data from', 'discontinued subjects will be used to impute missing data for other discontinued subjects.', 'Similarly, the available data from not discontinued subjects will be used to impute data for', 'such subjects where the Week 16 value is missing.', 'For not discontinued subjects, the stepwise multiple imputations procedure will be conducted', 'in the same way as specified for the imputation of the underlying EASI values in the primary', 'analysis of the secondary estimand for the binary endpoints.', 'For discontinued subjects, it is expected that the number of subjects with retrieved data at', 'Week 16 will be too small to facilitate the same imputation model as mentioned just above.', 'Consequently, an imputation model with only region and baseline effects (IGA as a factor and', 'baseline SCORAD / DLQI as a covariate) will be applied for discontinued subjects. Some', 'factors may have to be omitted, depending on the observed data, e.g. if retrieved subjects only', 'come from one region or if they all have the same baseline severity.', 'Each of the 100 imputed datasets will be analysed and the resulting estimates and standard', 'errors pooled as described in the sensitivity analyses for the primary estimand for the', 'continuous secondary endpoints.', 'Sensitivity analyses for the secondary estimand (continuous secondary endpoints)', 'Rather than assuming that observations are missing at random, it is assumed that missing data', 'from subjects in the tralokinumab arm who have/have not discontinued treatment prior to', 'Week 16 will resemble data from subjects from the placebo arm who have/have not', 'discontinued treatment prior to Week 16.', 'Imputation of missing data at Week 16 will be done using a pattern mixture model where', 'missing data in the tralokinumab arm as well as the placebo arm will be imputed from the', 'placebo arm (copy-reference approach). With this exemption, the multiple imputation', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}